Alveron Pharma Secures EUR 5 Million in Seed Extension Financing
The capital provided by this new financing enables Alveron to accelerate important development activities that support OKL-1111’s readiness for further clinical studies to demonstrate safety and proof-of-concept efficacy in patients.
Alveron Pharma | 07/12/2024 | By Aishwarya | 173
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy